KiOmed Pharma is currently developing an animal-free chitosan-based viscosupplement to address a major issue in the joint health market: Osteoarthritis.
The gel viscosupplement and its novel chitosan-based formulation technologies is a breakthrough innovation on the viscosupplementation market, which is based on animal-free, medical grade biomaterials developed by KiOmed Pharma. The formulation found in the gel viscosupplement is the culmination of five years of high quality R&D programs and is protected by a patent with exclusive rights belonging to KiOmed Pharma.
This implantable intra-articular device is safe and has shown high single dose efficacy in preclinical proof-of-concept. The formulation used in the gel viscosupplement exhibits sustained chondroprotective efficacy through enhanced shock absorption and is able to restore the rheological profile of healthy synovial fluid.
This thermosensitive hydrogel is easy to inject at room temperature and exhibits interesting lubricant and bioadhesive properties for restoring the rheological profile of healthy synovial fluid.